Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial and Will Soon Begin Phase 2a Kidney Dialysis and Phase 1 Fabry Disease Trials**



Tartisan Resources Corp. to Acquire Canadian Arrow Mines Limited


  • Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
  • Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan


Tartisan logo copy

Hub On AGORACOM / Read Release

Message: Anacetrapib Officially Bites the Dust

"Do we know how Apabatalone fares with respect to lowering non-HDL cholesterol levels? I have read elsewhere that any significant improvement in non-HDL likely means significant reduction in heart attack risk.

Apabetalone effects on non-HDL cholesterol? In the Atherosclerosis peer-reviewed article from 2016 (news released here) and indexed on PubMed here, Table I summarizes the effects of apabetalone on lipoproteins in the pooled SUSTAIN and ASSURE trials. Both apabetalone and placebo groups experienced a ~10% decrease in their baseline LDL-cholesterol levels after ~6 months of treatment. There was no significant difference in LDL-cholesterol levels between the apabetalone and placebo groups. Keep in mind both groups were on statin therapy already.

As for lowering non-HDL cholesterol (i.e. LDL-cholesterol) and its effects on cardiovascular events......take a look at the recently published FOURIER PCSK9 antibody trial "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease." These patients were already on an "optimized regimen of lipid-lowering therapy, which was defined as preferably a high-intensity statin but must have been at least atorvastatin at a dose of 20 mg daily or its equivalent, with or without ezetimibe."  This Evolocumab (aka Repatha) therapy dropped baseline LDL-cholesterol from by ~56 mg/dL,  reducing baseline levels of 92 mg/dL to ~36 mg/dL. That is a HUGE effect. This dramatic drop in LDL-cholesterol reduced 3-point MACE (heart attack, stroke, cardiovascular death) by 20%. Break this down further and one sees that heart attacks were significantly reduced by 27%, strokes were significantly reduced by 21%, and cardiovascular death was non-significantly increased by 5%. 

So long story short....it is quite possible that the modest effects of the CETP inhibitor anacetrapib on reducing heart attack (13% significant reduction in heart attack, non-significant 8% reduction in cardiovascular death, no effect on stroke; see NEJM article) are due to the effect of anacetrapib to lower LDL-cholesterol by 17 mg/dL in the REVEAL study and has nothing to do with the increase of HDL by anacetrapib.


New Message
Please login to post a reply